1. Home
  2. MIRM vs HUBCW Comparison

MIRM vs HUBCW Comparison

Compare MIRM & HUBCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • HUBCW
  • Stock Information
  • Founded
  • MIRM 2018
  • HUBCW N/A
  • Country
  • MIRM United States
  • HUBCW Israel
  • Employees
  • MIRM N/A
  • HUBCW 223
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • HUBCW
  • Sector
  • MIRM Health Care
  • HUBCW
  • Exchange
  • MIRM Nasdaq
  • HUBCW Nasdaq
  • Market Cap
  • MIRM 1.9B
  • HUBCW N/A
  • IPO Year
  • MIRM 2019
  • HUBCW N/A
  • Fundamental
  • Price
  • MIRM $41.31
  • HUBCW $0.02
  • Analyst Decision
  • MIRM Strong Buy
  • HUBCW
  • Analyst Count
  • MIRM 11
  • HUBCW 0
  • Target Price
  • MIRM $58.55
  • HUBCW N/A
  • AVG Volume (30 Days)
  • MIRM 437.9K
  • HUBCW N/A
  • Earning Date
  • MIRM 05-12-2025
  • HUBCW N/A
  • Dividend Yield
  • MIRM N/A
  • HUBCW N/A
  • EPS Growth
  • MIRM N/A
  • HUBCW N/A
  • EPS
  • MIRM N/A
  • HUBCW N/A
  • Revenue
  • MIRM $336,888,000.00
  • HUBCW N/A
  • Revenue This Year
  • MIRM $29.51
  • HUBCW N/A
  • Revenue Next Year
  • MIRM $20.27
  • HUBCW N/A
  • P/E Ratio
  • MIRM N/A
  • HUBCW N/A
  • Revenue Growth
  • MIRM 80.76
  • HUBCW N/A
  • 52 Week Low
  • MIRM $23.83
  • HUBCW N/A
  • 52 Week High
  • MIRM $54.23
  • HUBCW N/A
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 47.80
  • HUBCW N/A
  • Support Level
  • MIRM $38.22
  • HUBCW N/A
  • Resistance Level
  • MIRM $39.87
  • HUBCW N/A
  • Average True Range (ATR)
  • MIRM 2.08
  • HUBCW 0.00
  • MACD
  • MIRM 0.34
  • HUBCW 0.00
  • Stochastic Oscillator
  • MIRM 70.54
  • HUBCW 0.00

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About HUBCW Hub Cyber Security Ltd. Warrant 2/27/28

Hub Cyber Security Ltd is engaged in the development of cyber products, software, quality systems, reliability, and risk management. It operates in several countries and provides cybersecurity computing appliances as well as a wide range of cybersecurity professional services. The company has two operating segments: the Product and Technology Segment, and the Professional Services Segment. The majority of its revenue comes from the professional services segment, which provides data and cybersecurity, system security and reliability solutions, as well as related services such as consulting, planning, training, integration, and ongoing servicing of cybersecurity, risk management, system quality, reliability, and security projects, including fully managed corporate cybersecurity services.

Share on Social Networks: